Gallamini Andrea, Borra Anna
Research, innovation and statistics department - A Lacassagne Cancer Centre - Nice, France.
Haemato-oncology department- A Lacassagne Cancer Centre - Nice, France.
Mediterr J Hematol Infect Dis. 2017 Apr 15;9(1):e2017029. doi: 10.4084/MJHID.2017.029. eCollection 2017.
In the present review, the reader will be led to the most relevant observations that prompted oncologists and haematologist to consider FDG-PET/CT as a new paradigm for FL management in clinical practice. The role of functional imaging in lymphoma staging, restaging, prognostication, and metabolic tumour volume computing will be reviewed in detail. Moreover, a special focus will be addressed to technical and practical aspects of PET scan reporting, which have been set during the last decade to ensure the reproducibility of the therapeutic results. Finally, the predictive role of PET/CT on long-term treatment outcome will be compared with another well-known prognosticator as minimal residual disease (MRD) detection by Immunoglobulin gene rearrangement assessment.
在本综述中,读者将了解到促使肿瘤学家和血液学家将氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)视为临床实践中滤泡性淋巴瘤(FL)管理新范式的最相关观察结果。将详细回顾功能成像在淋巴瘤分期、再分期、预后评估和代谢肿瘤体积计算中的作用。此外,还将特别关注正电子发射断层扫描(PET)扫描报告的技术和实际方面,这些方面是在过去十年中确定的,以确保治疗结果的可重复性。最后,将PET/CT对长期治疗结果的预测作用与另一种著名的预后指标——通过免疫球蛋白基因重排评估检测微小残留病(MRD)进行比较。